Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics

15-Jun-2015 - United Kingdom

Quotient Clinical has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for Corcept Therapeutics Incorporated, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers. The Enabled-FIH program integrated formulation development, real-time GMP manufacturing and clinical testing, using a single adaptive protocol to assess single and multiple dose safety, pharmacokinetics, and proof of pharmacological effect. The clinical timeline for the first-in-human dose through to completion of the program was only 7 months. CORT125134 was proven to be safe and well tolerated at the doses tested, and pharmacological effect was demonstrated. The drug is now progressing into the next stages of development. 

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances